further research will be needed to refine and evolve our assessment and management of these patients such that outcomes improve and the variation in practice patterns is reduced.
TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies TO THE EDITOR: Following the publication of our metaanalysis on TGFBR1*6A and cancer [1] , several colleagues have shared with us the results of their own unpublished casecontrol studies. We are now reporting all the data made available to us as of November 2003-a total of 12 case-control studies that included 3,451 controls and 4,399 cases ( Table 1) . The additional data come from several sources: (1) Dr Michael Reiss from the Cancer Institute of New Jersey genotyped 98 women with sporadic breast cancer and 91 age-matched healthy women from New Haven County in Connecticut. Ninety-one percent of the women were white, 7% were African American, and 2% were of other racial/ethnic groups. Blood samples were collected as part of a parent case-control study to assess the relationship between serum organochlorines and breast cancer risk. 5) We have also included the Northwestern Cancer Genetics Program unpublished data from Chicago, IL, which includes 121 consecutive cases of breast, colon, and ovarian cancer, and 123 controls of similar ethnic background. Combined analysis of the 12 studies shows that TGFBR1*6A allelic frequency among cases (0.090) is 27% higher than among controls (0.071; P ϭ .0005). TGFBR1*6A carriers have a 24% increased risk of cancer (odds ratio, 1.24; 95% CI, 1.10 to 1.40), which is almost identical to the 26% increased risk found previously [1] . As in our previous report, the overall cancer risk is significantly increased for both TGFBR1*6A heterozygotes (19%) and homozygotes (70%; Table 2 ). TGFBR1*6A carriers (Table 3) . Inclusion of these additional studies addresses the crucial issue of publication bias discussed in our recent communication [1] . Overall, only three of the 12 case control studies reported here showed an association between TGFBR1*6A and cancer. This strongly argues against a publication bias. The results of this second meta-analysis that included 7,850 individuals reinforce our previous findings and confirm TGFBR1*6A as the most common tumor susceptibility allele reported to date that increases the risk of breast, ovarian, and colorectal cancer. Abbreviation: OR, odds ratio.
‫ء‬
Included in the total number are rare TGFBR1 exon 1 polymorphisms such as *5A, *7A, *8A, and *10A. 
